This analysis by Marketdata examines a controversial $4 billion healthcare service sector — infertility services. This loosely regulated “baby business” has come under the spotlight lately, as the Nadya Suleman (OctoMom) case brought up issues of unethical practices by some fertility doctors practicing “assisted reproductive technology” (ART) and implanting multiple embryos.
ART now produces more than 50,000 babies per year in the U.S. via 142,000 IVF procedures (nearly tripled since 1999), and demand is growing from the ranks of 7+ million infertile women, many of which delayed childbearing due to careers. There are 483 U.S. fertility clinics, 100+ sperm banks, an unknown number of egg donors, and 1,700 reproductive endocrinologists competing for the business, which is lucrative. In addition, the global market for fertility drugs tops $1 billion. Only one corporate “chain”, IntegraMed, exists, as most programs are run by small MD practices or are part of a hospital or University.
This unique new study by Marketdata examines the nature/evolution of the business, national receipts/growth from 1988 to 2013 forecast, extensive infertile customer demographics, key industry trends, industry regulation, pricing, industry consolidation, insurance coverage, ethical issues and calls for reform, effects of the recession, and more. The study presents the findings of Marketdata’s mail/phone survey of fertility clinic managers, with average costs and number of specific diagnostic procedures. Contains results of the latest (2006 & 2007) CDC ART surveys, with IVF success rates, plus a name/address directory of 400+ fertility clinics, as well as European ART cycles survey data. Examines the sperm banks, egg donors, and fertility drugs markets, and surrogacy programs.
This study is believed to be one of the few in-depth publicly available business analyses that exists of this market. It’s ALL here in one place.
(0 items)
